| Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02) (NCT04305054) | Merck Sharp & Dohme LLC | 2020-07-01 |
| Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033) (NCT04384107) | Merck Sharp & Dohme LLC | 2020-07-01 |
| A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33) (NCT04317066) | Merck Sharp & Dohme LLC | 2020-06-26 |
| Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) (NCT04303169) | Merck Sharp & Dohme LLC | 2020-06-26 |
| Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02) (NCT04305041) | Merck Sharp & Dohme LLC | 2020-06-26 |
| Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026) (NCT04303156) | Merck Sharp & Dohme LLC | 2020-06-18 |
| Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011) (NCT04152863) | Merck Sharp & Dohme LLC | 2020-06-05 |
| Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006) (NCT04370873) | Merck Sharp & Dohme LLC | 2020-06-05 |
| Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) (NCT04246177) | Merck Sharp & Dohme LLC | 2020-05-22 |
| Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) (NCT04241185) | Merck Sharp & Dohme LLC | 2020-05-19 |
| Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047) (NCT04221945) | Merck Sharp & Dohme LLC | 2020-05-12 |
| Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042) (NCT04193176) | Merck Sharp & Dohme LLC | 2020-05-10 |
| Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036) (NCT04223752) | Merck Sharp & Dohme LLC | 2020-04-17 |
| Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019) (NCT04233216) | Merck Sharp & Dohme LLC | 2020-03-18 |
| Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002) (NCT04220866) | Merck Sharp & Dohme LLC | 2020-03-04 |
| A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005) (NCT04195750) | Merck Sharp & Dohme LLC | 2020-02-27 |
| Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049) (NCT04199689) | Merck Sharp & Dohme LLC | 2020-02-27 |
| Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018) (NCT04223791) | Merck Sharp & Dohme LLC | 2020-02-18 |
| Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017) (NCT04223778) | Merck Sharp & Dohme LLC | 2020-02-18 |
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) (NCT04191096) | Merck Sharp & Dohme LLC | 2020-02-12 |
| A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010) (NCT04199104) | Merck Sharp & Dohme LLC | 2020-02-05 |
| KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C) (NCT04165096) | Merck Sharp & Dohme LLC | 2020-01-21 |
| MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042) (NCT04129398) | Merck Sharp & Dohme LLC | 2019-12-27 |
| Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) (NCT04191135) | Merck Sharp & Dohme LLC | 2019-12-19 |
| KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) (NCT04165070) | Merck Sharp & Dohme LLC | 2019-12-19 |
| KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01) (NCT04165798) | Merck Sharp & Dohme LLC | 2019-12-19 |
| KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B) (NCT04165083) | Merck Sharp & Dohme LLC | 2019-12-19 |
| A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17) (NCT04153565) | Merck Sharp & Dohme LLC | 2019-12-09 |
| A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001) (NCT04168190) | Merck Sharp & Dohme LLC | 2019-12-06 |
| Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007) (NCT04123366) | Merck Sharp & Dohme LLC | 2019-11-18 |
| Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED) (NCT03921424) | Merck Sharp & Dohme LLC | 2019-11-05 |
| Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study (NCT04716933) | Merck Sharp & Dohme LLC | 2019-11-05 |
| A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001) (NCT04135352) | Merck Sharp & Dohme LLC | 2019-11-04 |
| Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study (NCT04676412) | Merck Sharp & Dohme LLC | 2019-10-23 |
| Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study (NCT04865289) | Merck Sharp & Dohme LLC | 2019-10-22 |
| Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059) (NCT04029480) | Merck Sharp & Dohme LLC | 2019-10-08 |
| Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) (NCT03740178) | Merck Sharp & Dohme LLC | 2019-09-27 |
| Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016) (NCT04003103) | Merck Sharp & Dohme LLC | 2019-09-19 |
| Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045) (NCT04054193) | Merck Sharp & Dohme LLC | 2019-09-09 |
| Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025) (NCT04031846) | Merck Sharp & Dohme LLC | 2019-09-04 |
| Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026) (NCT04016714) | Merck Sharp & Dohme LLC | 2019-08-28 |
| Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030) (NCT03940586) | Merck Sharp & Dohme LLC | 2019-08-08 |
| Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) (NCT03834493) | Merck Sharp & Dohme LLC | 2019-07-28 |
| Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303) (NCT03924895) | Merck Sharp & Dohme LLC | 2019-07-24 |
| Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169) (NCT03909165) | Merck Sharp & Dohme LLC | 2019-07-23 |
| A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008) (NCT03976362) | Merck Sharp & Dohme LLC | 2019-06-28 |
| Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) (NCT03976323) | Merck Sharp & Dohme LLC | 2019-06-28 |
| A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) (NCT03948763) | Merck Sharp & Dohme LLC | 2019-06-26 |
| Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008) (NCT03976375) | Merck Sharp & Dohme LLC | 2019-06-26 |
| Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024) (NCT03885934) | Merck Sharp & Dohme LLC | 2019-06-25 |
| Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867) (NCT03924869) | Merck Sharp & Dohme LLC | 2019-06-25 |
| Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040) (NCT03930615) | Merck Sharp & Dohme LLC | 2019-06-21 |
| Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) (NCT03893448) | Merck Sharp & Dohme LLC | 2019-06-19 |
| A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) (NCT03918278) | Merck Sharp & Dohme LLC | 2019-06-19 |
| Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE) (NCT03950622) | Merck Sharp & Dohme LLC | 2019-06-13 |
| Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866) (NCT03924856) | Merck Sharp & Dohme LLC | 2019-06-13 |
| Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020) (NCT03950856) | Merck Sharp & Dohme LLC | 2019-06-12 |
| Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937) (NCT03867084) | Merck Sharp & Dohme LLC | 2019-05-28 |
| A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China Extension (NCT04525885) | Merck Sharp & Dohme LLC | 2019-05-17 |
| Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) (NCT03898180) | Merck Sharp & Dohme LLC | 2019-05-06 |
| Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) (NCT03834519) | Merck Sharp & Dohme LLC | 2019-05-02 |
| Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921) (NCT03834506) | Merck Sharp & Dohme LLC | 2019-05-02 |
| Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004) (NCT03873038) | Merck Sharp & Dohme LLC | 2019-04-29 |
| Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024) (NCT03903562) | Merck Sharp & Dohme LLC | 2019-04-27 |
| Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002) (NCT03859739) | Merck Sharp & Dohme LLC | 2019-04-26 |
| Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) (NCT03884101) | Merck Sharp & Dohme LLC | 2019-04-11 |
| Safety and Tolerability of Gefapixant (MK-7264) in Participants With Obstructive Sleep Apnea (MK-7264-039) (NCT03882801) | Merck Sharp & Dohme LLC | 2019-04-10 |
| Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028) (NCT03848065) | Merck Sharp & Dohme LLC | 2019-04-02 |
| Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630) (NCT03833167) | Merck Sharp & Dohme LLC | 2019-04-01 |
| Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006) (NCT03829319) | Merck Sharp & Dohme LLC | 2019-03-25 |
| Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015) (NCT03830333) | Merck Sharp & Dohme LLC | 2019-03-20 |
| Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001) (NCT03833427) | Merck Sharp & Dohme LLC | 2019-03-18 |
| Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007) (NCT03829332) | Merck Sharp & Dohme LLC | 2019-03-13 |
| Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003) (NCT03820986) | Merck Sharp & Dohme LLC | 2019-03-12 |
| Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003) (NCT03840174) | Merck Sharp & Dohme LLC | 2019-03-08 |
| Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058) (NCT03843632) | Merck Sharp & Dohme LLC | 2019-03-01 |
| Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913) (NCT03783078) | Merck Sharp & Dohme LLC | 2019-02-25 |
| Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014) (NCT03745989) | Merck Sharp & Dohme LLC | 2019-02-22 |
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) (NCT03797326) | Merck Sharp & Dohme LLC | 2019-02-12 |
| A Study of MK-8527 in Human Immunodeficiency Type 1 Virus (HIV-1) Infected Participants (MK-8527-002) (NCT03615183) | Merck Sharp & Dohme LLC | 2019-02-11 |
| A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014) (NCT03217565) | Merck Sharp & Dohme LLC | 2019-02-06 |
| Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) (NCT03715205) | Merck Sharp & Dohme LLC | 2019-01-31 |
| Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004) (NCT03776136) | Merck Sharp & Dohme LLC | 2019-01-30 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE) (NCT03731182) | Merck Sharp & Dohme LLC | 2019-01-23 |
| First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study (NCT03881111) | Merck Sharp & Dohme LLC | 2019-01-21 |
| A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018) (NCT03176134) | Merck Sharp & Dohme LLC | 2019-01-20 |
| A Study of Single Doses of Frespaciguat (MK-5475) on Pulmonary Vascular Resistance (MK-5475-002) (NCT03744637) | Merck Sharp & Dohme LLC | 2019-01-18 |
| Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002) (NCT03713593) | Merck Sharp & Dohme LLC | 2018-12-31 |
| Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) (NCT03725059) | Merck Sharp & Dohme LLC | 2018-12-27 |
| Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) (NCT03711032) | Merck Sharp & Dohme LLC | 2018-12-24 |
| Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002) (NCT03739138) | Merck Sharp & Dohme LLC | 2018-12-18 |
| Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) (NCT03765918) | Merck Sharp & Dohme LLC | 2018-12-17 |
| A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK) (NCT03692871) | Merck Sharp & Dohme LLC | 2018-12-14 |
| Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002) (NCT03742895) | Merck Sharp & Dohme LLC | 2018-12-12 |
| Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029) (NCT03643952) | Merck Sharp & Dohme LLC | 2018-12-06 |
| Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555) (NCT03665597) | Merck Sharp & Dohme LLC | 2018-11-19 |
| Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) (NCT03675737) | Merck Sharp & Dohme LLC | 2018-11-08 |
| Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension (NCT04859582) | Merck Sharp & Dohme LLC | 2018-11-08 |
| A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038) (NCT03696108) | Merck Sharp & Dohme LLC | 2018-10-31 |
| Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) (NCT03635567) | Merck Sharp & Dohme LLC | 2018-10-25 |